Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

M Ritchie, L Tchistiakova, N Scott - MAbs, 2013 - Taylor & Francis
The use of antibody-drug conjugates (ADCs) as a therapeutic platform to treat cancer has
recently gained substantial momentum. This therapeutic modality has the potential to increase …

A general approach to site-specific antibody drug conjugates

…, R Dushin, M Leal, L Tchistiakova… - Proceedings of the …, 2014 - National Acad Sciences
Using an expanded genetic code, antibodies with site-specifically incorporated nonnative
amino acids were produced in stable cell lines derived from a CHO cell line with titers over 1 g/…

Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration

…, C Corcoran, LA Collins-Racie, L Tchistiakova… - Molecular and cellular …, 2009 - Elsevier
… Serum sex hormone binding gobulin (SHBG) levels were measured by an immunofluorometric
assay that has a sensitivity of 6.25 nmol/L. Body composition was assessed at baseline …

[HTML][HTML] Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer

…, HP Gerber, C May, PA Moore, L Tchistiakova, L Bloom - Antibodies, 2016 - mdpi.com
Bispecific antibodies offer a promising approach for the treatment of cancer but can be
challenging to engineer and manufacture. Here we report the development of PF-06671008, an …

Fundamental characteristics of the immunoglobulin VH repertoire of chickens in comparison with those of humans, mice, and camelids

…, E Cummins, L Tchistiakova, L Bloom… - The Journal of …, 2012 - journals.aai.org
… In chickens, single functional v-genes exist for both the L and H chains, containing
unique V L –J L , V H –J H , and D segments (8, 20, 21). To use a restricted v-gene germline …

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

…, Y Vugmeyster, TP Hickling, L Tchistiakova… - MAbs, 2012 - Taylor & Francis
Advances in recombinant antibody technology and protein engineering have provided the
opportunity to reduce antibodies to their smallest binding domain components and have …

[HTML][HTML] Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural …

…, W Somers, DS Gill, L Mosyak, L Tchistiakova - Journal of Biological …, 2013 - ASBMB
The immunoglobulin new antigen receptors (IgNARs) are a class of Ig-like molecules of the
shark immune system that exist as heavy chain-only homodimers and bind antigens by their …

Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics

…, M Kavosi, M Wang, DM O'Hara, L Tchistiakova… - MAbs, 2018 - Taylor & Francis
A large body of data exists demonstrating that neonatal Fc receptor (FcRn) binding of an
IgG via its Fc CH2-CH3 interface trends with the pharmacokinetics (PK) of IgG. We have …

Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside …

…, N Piche, DD Pittman, J Paulsen, L Tchistiakova… - Journal of molecular …, 2009 - Elsevier
… A second family of improved clones had a different motif at positions 99–100a composed
of L/V–D–S/G or L–V–G/S sequences. The T99K/R/L and T100V/D mutations represent …

Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis

…, K Wallace, Y She, S Kwak, LA Tchistiakova… - Neurobiology of …, 2006 - Elsevier
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease leading to
motor neuron cell death, but recent studies suggest that non-neuronal cells may contribute to …